ProQR Therapeutics (PRQR) Cash from Investing Activities (2013 - 2026)

ProQR Therapeutics (PRQR) has reported Cash from Investing Activities for 14 consecutive years, with -$186624.5 the latest figure, recorded in Q1 2026.

• Quarterly Cash from Investing Activities rose 26.79% year-over-year to -$186624.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 million (down 107.15% YoY) and the FY2025 annual result came in at -$1.2 million, up 74.96% from the prior year.
• Cash from Investing Activities improved to -$186624.5 in Q1 2026 per PRQR's latest filing, from -$598563.9 in the prior quarter.
• Over the last five years, Cash from Investing Activities for PRQR reached as high as $19.0 million in Q3 2024 and fell as low as -$20.2 million in Q1 2024.
• A 5-year average of -$112523.6 and a median of -$262867.4 in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 26215.79% — and 2024, when it slumped 19823.6%.
• Year by year, Cash from Investing Activities stood at $21621.1 in 2022, then surged by 26215.79% to $5.7 million in 2023, then tumbled by 155.76% to -$3.2 million in 2024, then jumped by 81.13% to -$598563.9 in 2025, then surged by 68.82% to -$186624.5 in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$186624.5, -$598563.9, and -$192314.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.